Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Chimpanzee Adenovirus Vector Ebola Vaccine

(2017) Julie E. Ledgerwood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ebola virus disease candidate vaccines under evaluation in clinical trials

(2016) Karen A. Martins et al.   Expert Review of Vaccines

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

(2016) Milagritos D Tapia et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

(2016) Olga De Santis et al.   LANCET INFECTIOUS DISEASES

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

(2016) Selidji T. Agnandji et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

(2016) Katie Ewer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

(2015) Feng-Cai Zhu et al.   LANCET

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

(2015) Ana Maria Henao-Restrepo et al.   LANCET

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

(2015) Angela Huttner et al.   LANCET INFECTIOUS DISEASES

Ebola Virus Disease — Sierra Leone and Guinea, August 2015

(2015) Sara Hersey et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Emergence of Zaire Ebola Virus Disease in Guinea

(2014) Sylvain Baize et al.   NEW ENGLAND JOURNAL OF MEDICINE

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

(2010) J.E. Ledgerwood et al.   VACCINE